Oncotarget


2024 Press Releases

B7-H4 as a Therapeutic Target in Adenoid Cystic Carcinoma



2024-12-04

These results provide a robust rationale to investigate B7-H4 as a therapeutic target for B7-H4 expressing ACC.


 

BUFFALO, NY - December 4, 2024 – A new editorial was published in Oncotarget's Volume 15 on November 22, 2024, entitled “B7-H4: A potential therapeutic target in adenoid cystic carcinoma.

Researchers Luana Guimaraes de Sousa and Renata Ferrarotto from The University of Texas MD Anderson Cancer Center made an important discovery about adenoid cystic carcinoma (ACC), a rare and... continue reading >>

Mesenchymal Stem Cells in Cancer Immunotherapy: Promises and Challenges



2024-12-03

MSCs hold great promise as a therapeutic tool in cancer immunotherapy due to their immunomodulatory properties, tumor-homing abilities, and potential as carriers for delivering therapeutic agents.

 


BUFFALO, NY - December 3, 2024 –
A new review was published in Oncotarget's Volume 15 on November 22, 2024, entitled “Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists."

Authored by Theia Minev, Shani Balbuena, Jaya Mini Gill,
... continue reading >>

Persistence Landscapes: A Path to Unbiased Radiological Interpretation



2024-11-27

“Persistence landscapes, a sophisticated tool from topological data analysis, offer a promising approach to address biases in radiological interpretation and AI model development.”


 

BUFFALO, NY - November 27, 2024 – A new editorial was published in Oncotarget's Volume 15 on November 12, 2024, entitled “Persistence landscapes: Charting a path to unbiased radiological interpretation.

In this editorial, Yashbir Singh, Colleen Farrelly, Quincy A. Hathaway, and Gunnar Carlsson from the Department
... continue reading >>

Visualizing Radiological Data Bias with Persistence Images



2024-11-25

“Persistence images represent a powerful new tool in our ongoing efforts to visualize, understand, and mitigate biases in radiological data interpretation and AI model development.”


 

BUFFALO, NY - November 25, 2024 – A new editorial was published in Oncotarget's Volume 15 on November 12, 2024, entitled, “Visualizing radiological data bias through persistence images.

This editorial highlights a powerful tool called "persistence images," which could improve how medical imaging and artificial... continue reading >>

Persistence Barcodes: Reducing Bias in Radiological Analysis



2024-11-20

“Persistence barcodes emerge as a promising tool in radiological analysis, offering a novel approach to reduce bias and uncover hidden patterns in medical imaging.”


 

BUFFALO, NY - November 20, 2024 – A new editorial was published in Oncotarget's Volume 15 on November 12, 2024, entitled, “Persistence barcodes: A novel approach to reducing bias in radiological analysis.”

 

This editorial, authored by Yashbir Singh, Colleen Farrelly, Quincy A. Hathaway and Gunnar Carlsson from the Department of... continue reading >>

Reducing Bias in Radiology with Topological Data Analysis



2024-11-18

“By providing a more comprehensive, robust, and interpretable framework for analyzing medical imaging data, TDA has the potential to enhance the accuracy and fairness of radiological assessments.”



BUFFALO, NY - November 18, 2024 – A new editorial was published in Oncotarget's Volume 15 on November 12, 2024, entitled, “Mitigating bias in radiology: The promise of topological data analysis and simplicial complexes.”

 

In this publication, researchers Yashbir Singh, Colleen Farrelly, Quincy A.... continue reading >>

Extracellular Matrix and Tumor-Immune Interactions: Challenges & Opportunities



2024-11-12

“This review explores our current understanding of how ECM geometry influences the behaviors of both immune cells and tumor cells, which in turn impacts treatment efficacy and cancer evolutionary progression.”


 

BUFFALO, NY - November 12, 2024 – A new review was published in Oncotarget's Volume 15 on November 7, 2024, entitled “Understanding the interplay between extracellular matrix topology and tumor-immune interactions: Challenges and opportunities.

This comprehensive review by researchers... continue reading >>

Navigating Bias in AI-Driven Cancer Detection



2024-11-11

“As we eagerly adopt Al models, we need to take a moment to think about the potential biases that they may contain.”


 

BUFFALO, NY - November 11, 2024 – A new editorial was published in Oncotarget's Volume 15 on November 7, 2024, titled “ Beyond the hype: Navigating bias in AI-driven cancer detection

In this editorial, researchers from the Mayo Clinic emphasize the need to address potential biases in Artificial Intelligence (AI) tools used for cancer detection to ensure fair and equitable... continue reading >>

Precision Medicine in SCLC: DLL3, ASC1, TTF-1, and Ki-67 Expression



2024-11-06

“This study presents an observational, cross-sectional analysis of 64 patients diagnosed with small cell lung cancer (SCLC) at a reference laboratory for thoracic pathology between 2022 and 2024.”


 

BUFFALO, NY - November 6, 2024 – A new research paper was published in Oncotarget's Volume 15 on October 11, 2024, entitled “Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC

This study, led by researchers from the Federal University of
... continue reading >>

Immunotherapy Success in KRAS G12C Adenosquamous Pancreatic Cancer



2024-11-04

“Here, we present a case of metastatic ASCP with a KRAS G12C mutation refractory to multiple lines of systemic therapy, including platinum-based chemotherapy and targeted inhibition of KRAS G12C.”


BUFFALO, NY - November 4, 2024 – A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled “A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy.

This case report highlights a remarkable and unexpected response ... continue reading >>

Tumor Dormancy Initiated by Lymphovascular Embolus



2024-10-30

“Both our experimental as well as observational studies indicate that in vivo lymphovascular tumor emboli and their in vitro spheroid equivalent initiate dormancy through these pathways.”


 

BUFFALO, NY- October 30, 2024 – A new research paper was published in Oncotarget's Volume 15 on October 11, 2024, entitled “Initiation of tumor dormancy by the lymphovascular embolus.”

 

Researchers Yin Ye, Justin Wang, Michael G. Izban, Billy R. Ballard, and Sanford H. Barsky from Meharry Medical College... continue reading >>

Complete Response to Encorafenib + Binimetinib in BRAF V600E-Mutant Tumor



2024-10-29

“This case report highlights the importance of full tumor genotyping to identify potentially actionable targets in rare tumors such as malignant glomus tumors.”


 

BUFFALO, NY- October 29, 2024 – A new case report was published in Oncotarget's Volume 15 on October 11, 2024, entitled “Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor.”

 

As highlighted in the abstract, glomus tumors (GT) are rare mesenchymal neoplasms originating in dermal ... continue reading >>

How Blood Cancer Cells Rewire to Evade Drug Treatment



2024-10-23

“[...] drugs that target individual signalling pathways in AML often fail to stop proliferation malignant growth, due to the wide variety, redundancy and cross talk between multiple pathways regulating and differentiation.”


 

BUFFALO, NY- October 23, 2024 – A new editorial was published in Oncotarget's Volume 15 on October 11, 2024, entitled, “Gene regulatory network and signalling pathway rewiring: How blood cancer cells shift their shapes to evade drug treatment.”

 

As highlighted in the... continue reading >>

Tribute to Dr. Mikhail (Misha) Blagosklonny



2024-10-22


It is with great sadness and heavy heart that we announce the recent passing of Dr. Mikhail (Misha) V. Blagosklonny, our beloved Editor-in-Chief. Misha succumbed to metastatic lung cancer after a courageous battle.

 

Dr. Blagosklonny will be remembered as a brilliant and extraordinary scientist who dedicated his life to science. He was a visionary thinker, who made highly original contributions to cancer and aging research that were often ahead of their time. 

 

Dr. Blagosklonny was born into... continue reading >>

Next-Gen Cell-Penetrating Antibodies for Tumor Targeting and RAD51 Inhibition



2024-10-21

“Overall, the data presented in this study affirm that humanizing 3E10 preserves its crucial biological properties essential for therapeutic efficacy.”


 

BUFFALO, NY- October 21, 2024 – A new research paper was published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition.”

 

As highlighted in the abstract, monoclonal antibody therapies for cancer have shown extraordinary clinical success in recent years. ... continue reading >>

Molecular Chaperones: Guardians of Tumor Suppressor Stability



2024-10-16

“Focusing on the holistic lifecycle of these proteins reveals commonalities between the widely diverse group of tumor suppressors, which is invaluable to inform therapy development for multiple cancers.”


BUFFALO, NY- October 16, 2024 – A new review was published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Molecular chaperones: Guardians of tumor suppressor stability and function.”

As highlighted in the abstract of this paper, "tumor suppressor" describes a diverse set of genes... continue reading >>

TP53 Mutated AML: Transplant or No Transplant



2024-10-11

“In summary, this study reported improved survival when allo-HTC was performed in CR1 versus after later lines of therapy.”


BUFFALO, NY- October 11, 2024 – A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, “Transplant or no transplant for TP53 mutated AML.”

As highlighted in this editorial, TP53 mutations (mut) occur in 10–15% of acute myeloid leukemia (AML) cases, commonly associated with therapy-related AML (t-AML) and complex cytogenetics (CG). TP53-mut... continue reading >>

Zika Virus as a Treatment for Brain Cancer: A Systematic Review



2024-10-09

“Despite limited human evidence, it shows potential benefits.”


 

BUFFALO, NY- October 9, 2024 – A new review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Zika virus and brain cancer: Can Zika be an effective treatment for brain cancer? A systematic review.”

 

As highlighted in the introduction of this review, many studies have identified oncolytic viruses as a promising new class of therapeutic agents for central nervous system (CNS) tumors, particularly... continue reading >>

Lessons from ACDC-RP Trial: Designing Neoadjuvant Therapy Trials for Prostatectomy



2024-10-07

“While the ACDC-RP trial adds to the litany of negative trials in this disease space, there are key takeaways from this trial that can inform future clinical trial design.”


BUFFALO, NY- October 7, 2024 – A new editorial was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Lessons from the ACDC-RP trial: Clinical trial design for radical prostatectomy neoadjuvant therapy trials.”

As highlighted at the beginning of the editorial, clinical trials of neoadjuvant therapy have... continue reading >>

Exploring UBA1 Dysfunction in VEXAS Syndrome and Cancer



2024-10-03

“Ultimately, a thorough grasp of the pathogenesis of VEXAS, from genetic mutations to clinical manifestations, will be pivotal in devising safe and effective therapeutic strategies to fight this challenging disease.”

BUFFALO, NY- October 3, 2024 – A new research perspective was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “UBA1 dysfunction in VEXAS and cancer.”

As highlighted in the abstract of this paper, UBA1 is an X-linked gene that encodes one of the only two... continue reading >>

FOXM1 and PD-L1 in CDK4/6-MEK Resistance in Nerve Tumors



2024-10-01

We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent exciting future treatment options for MPNST patients.”

 

BUFFALO, NY- October 1, 2024 – A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6-MEK targeted therapy resistance in malignant peripheral nerve sheath tumors.”

 

As highlighted in the abstract of this paper, malignant peripheral nerve sheath... continue reading >>

The Role of Artificial Intelligence in Advancing Intratumoral Immunotherapy



2024-09-19

We explore how integrating these technologies could revolutionize personalized oncology.”

 

BUFFALO, NY- September 19, 2024 – A new editorial was published in Oncotarget's Volume 15 on September 17, 2024, entitled, “The emerging role of AI in enhancing intratumoral immunotherapy care.”

 

As highlighted in the abstract of this editorial, the emergence of immunotherapy (IO), and more recently, intratumoral IO, offers a novel approach to cancer treatment. This method enhances immune responses,... continue reading >>

ISR Activation & Apoptosis via HRI Kinase by PG3 and Other p53 Cancer Therapies



2024-09-18

Our results provide unique insights into the mechanism of action of PG3 as a novel cancer therapeutic targeting p53 pathway-like tumor suppression.”

BUFFALO, NY- September 18, 2024 – A new research paper was published in Oncotarget's Volume 15 on September 17, 2024, entitled, “Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics.”

As highlighted in the abstract of this study, restoration of the p53 pathway has... continue reading >>

Targeting CD47/SIRPα "Do Not Eat Me" Axis: Advances and Challenges in Cancer Therapy



2024-09-11

Numerous phagocytosis checkpoints and ‘do not eat me’ signals (i.e., CD47, CD24, MHC-I, PD-L1, STC1, and GD2) have recently been recognized as potential therapeutic targets.

 

BUFFALO, NY- September 11, 2024 – A new editorial was recently published in Oncotarget's Volume 15, on July 10, 2024, entitled, “The advances in targeting CD47/SIRPα 'do not eat me' axis and their ongoing challenges as an anticancer therapy.”

 

As discussed in this paper, the growing understanding of the tumor immune... continue reading >>

Next-Gen Vaccines Offer New Hope Against Glioblastoma



2024-09-09

Vaccines have been considered a promising approach for GBM for many years.”

 

BUFFALO, NY- September 9, 2024 – A new editorial was published in Oncotarget's Volume 15 on August 5, 2024, entitled, “Next-generation vaccines are showing promise against glioblastoma.”

 

As noted in this paper, glioblastoma (GBM) is a rare but highly lethal malignancy that predominantly affects adults. Each year, approximately 13,000 new GBM cases are diagnosed in the United States, with around 12,000 related... continue reading >>

Generative AI in Cancer Imaging: Revolutionizing Detection & Diagnosis



2024-09-06

This editorial explores its impact on expanding datasets, improving image quality, and enabling predictive oncology.”

BUFFALO, NY- September 6, 2024 – A new editorial was published in Oncotarget's Volume 15 on September 4, 2024, entitled, “Generative AI in oncological imaging: Revolutionizing cancer detection and diagnosis.”

Generative AI is revolutionizing oncological imaging, enhancing cancer detection and diagnosis. This editorial explores its impact on expanding datasets, improving image... continue reading >>

Case for Inflammatory Memory for Hematopoietic Stem and Progenitor Cells in AML Niche



2024-09-05

In this research perspective, we discuss recent work from our lab describing an active role of HSPCs in AML and the potential implications.”

BUFFALO, NY- September 5, 2024 – A new research perspective was published in Oncotarget's Volume 15 on September 4, 2024, entitled, “Trained and ready - the case for an inflammatory memory for hematopoietic stem and progenitor cells in the AML niche.”

As noted in the abstract of this paper, lifelong hematopoiesis is sustained by the crosstalk between... continue reading >>

The Targeting of WNT5B and WNT10B in Osteosarcoma



2024-09-04

As there is controversy over whether we should use WNT activators or WNT inhibitors to treat osteosarcoma, we hypothesize that it depends on whether the canonical or non-canonical pathways are activated, and this remains to be formally tested.”

BUFFALO, NY- September 4, 2024 – A new review was published in Oncotarget's Volume 15 on August 2, 2024, entitled, “Targeting WNT5B and WNT10B in osteosarcoma.”

As noted in the abstract of this paper, WNT signaling regulates osteosarcoma proliferation.... continue reading >>

Graph Filtration Learning Reveals New Dimensions in Hepatocellular Carcinoma Imaging



2024-08-30

In medical imaging, our understanding of hepatocellular carcinoma (HCC) has long been constrained by the limitations of pixel-based analysis.”

BUFFALO, NY- August 30, 2024 – A new editorial was published in Oncotarget's Volume 15 on July 24, 2024, entitled, “Beyond pixels: Graph filtration learning unveils new dimensions in hepatocellular carcinoma imaging.”

As traditional pixel-based methods reach their limits, Graph Filtration Learning (GFL) offers a novel approach to capturing complex... continue reading >>

miR-10b Inhibition: A Strategy for Treating Metastatic Breast Cancer



2024-08-28

“We have developed a nanodrug, termed MN-anti-miR10b, that delivers anti-miR-10b antisense oligomers to cancer cells.”


BUFFALO, NY- August 28, 2024 – A new research paper was published in Oncotarget's Volume 15 on August 26, 2024, entitled, “Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties.”

As stated within the Abstract of the paper, despite advances in breast cancer screening and treatment, the prognosis for metastatic disease remains dismal, with... continue reading >>

Artificial Intelligence: Revolutionizing Precision Oncology



2024-08-27

Properly leveraged AI-based techniques could herald a new era of precision medicine guided by non-invasive, imaging-based disease evaluation."


BUFFALO, NY- August 27, 2024 – A new editorial was published in Oncotarget's Volume 15 on August 26, 2024, entitled, “Artificial intelligence: A transformative tool in precision oncology.”

Artificial intelligence (AI) is revolutionizing society and healthcare, opening new possibilities for precision medicine. In oncology, immunotherapy (IO) has... continue reading >>

Genotype Matters: Tailored Screening for Germline CHEK2 Variants



2024-08-26

In our study, we postulated that these differences were driven by three common low-risk (LR) missense variants: p.I157T, p.S428F, and p.T476M, all of which have a BC odds ratio of <1.4.”

BUFFALO, NY- August 26, 2024 – A new editorial was published in Oncotarget's Volume 15 on July 10, 2024, entitled, “Genotype matters: Personalized screening recommendations for germline CHEK2 variants.”

Recognized as a moderate-risk gene, CHEK2—responsible for encoding the CHK2 protein, which plays a crucial... continue reading >>

Disrupting NKG2A:HLA-E Interactions for Enhanced Anti-Cancer Immunity



2024-08-21

[...] there is strong preclinical evidence that disruption of NKG2A interactions with HLA-E can stimulate both NK cell and cytotoxic T cell effector functions against cancer.”

BUFFALO, NY- August 21, 2024 – A new editorial was published in Oncotarget's Volume 15 on July 17, 2024, entitled, “Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity.”

Two studies using CRISPR screens in cancer cells identified HLA-E as a critical negative regulator of NK cell... continue reading >>

Role of the Gut Barrier in Colorectal Cancer Treatment



2024-08-19

“Herein we discuss how gut microbiota and microbial metabolites regulate basal inflammation levels in the gut and the healing process of the bowel after surgery.”


BUFFALO, NY- August 19, 2024 – A new review was published in Oncotarget's Volume 15 on August 14, 2024, entitled, “The gut barrier as a gatekeeper in colorectal cancer treatment.”

Colorectal cancer (CRC) is highly prevalent and a major cause of cancer-related deaths worldwide. The primary curative treatment for CRC is surgical... continue reading >>

Nanobody Inhibits Metastasis of Breast Tumor Cells to Lung in Mice



2024-08-15

“In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.”


BUFFALO, NY- August 15, 2024 – A new research paper was published in Oncotarget's Volume 15 on August 14, 2024, entitled, “A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice.”

The vacuolar H+-ATPase (V-ATPase) is an ATP-dependent proton pump that functions to control the pH of... continue reading >>

Response of BRAF-Mutated Spindle Cell Sarcoma to BRAF/MEK Inhibitors



2024-08-14

“This is the first report of spindle cell sarcoma BRAF V600E/S607T double-mutated, responding to a combination of B-Raf and MEK inhibitors.”


BUFFALO, NY- August 14, 2024 – A new case report was published in Oncotarget's Volume 15 on July 17, 2024, entitled, “Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors.”

As noted in the introduction of the Abstract, the BRAF V600E substitution predicts a cancer's sensitivity to... continue reading >>

New Directions in Targeting the Multifaceted BRAF in Cancer



2024-08-12

“Here we discuss the diverse forms of BRAF alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.”

BUFFALO, NY- August 12, 2024 – A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, “Targeting the multifaceted BRAF in cancer: New directions.”

In cancer patients, BRAF-targeting precision therapeutics are effective against Class I BRAF alterations (p.V600 hotspot mutations) in tumors such ... continue reading >>

TCR CDR3s and Renalase-1 Linked to Increased Melanoma Survival



2024-08-08

“These findings indicate that renalase-1 is a potential antigen for TCR recognition in melanoma and could be considered as a target for immunotherapy.”


BUFFALO, NY- August 8, 2024 – A new research paper was published in Oncotarget's Volume 15 on August 5, 2024, entitled, “Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival.”

As mentioned in the Abstract of this study, overexpression of the secretory protein renalase-1... continue reading >>

Dealing with Runaway Metastatic Disease



2024-08-07

“Metastatic disease remains a major issue in daily practice in oncology because the outcome is still often fatal.”



BUFFALO, NY - August 7, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on July 12, 2024, entitled, “How to deal with runaway metastatic disease?

In this new editorial, Justine Paris and Guilhem Bousquet from Université Paris Cité, Université Sorbonne Paris Nord, and APHP, Hôpital Avicenne, Oncologie médical, discussed how their research team have shown that... continue reading >>

INT-1B3 miR-193a-3p Mimic Boosts T Cell Immunity and Induces Tumor Cell Death



2024-08-05

INT-1B3 inhibited distant tumor metastasis and significantly prolonged survival.”

BUFFALO, NY- August 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 12, 2024, entitled, “INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death.”

In this study, researchers Chantal L. Duurland, Thijs de Gunst, Harm C. den Boer, Marion... continue reading >>

Prognostic and Therapeutic Insights on MIF, DDT, and CD74 in Melanoma



2024-07-26

“[...] we present the first study to retrospectively evaluate differential gene expression of MIF, DDT, and relevant pathway markers in regard to clinical outcomes in patients with melanoma.”

 

 

BUFFALO, NY- July 26, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 19, 2024, entitled, “Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.”

 

Macrophage Migration Inhibitory Factor (MIF) and its homolog D-dopachrome Tautomerase (DDT) have been... continue reading >>

The KIT M541L Variant in Patients With Mastocytosis



2024-07-24

“This study uniquely examines the prevalence and impact of the KIT M541L variant in both adult and pediatric patients with mastocytosis further stratified by disease variant.”

 

 

BUFFALO, NY- July 24, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 22, 2024, entitled, “Prevalence and impact of the KIT M541L variant in patients with mastocytosis.”

 

Activating mutations in KIT, particularly D816V, have been associated with mastocytosis. Additionally, expression of... continue reading >>

Oncotarget Welcomes New Editorial Board Members



2024-07-22

Oncotarget is also offering a 50% discount on publication fees until the end of the year.

BUFFALO, NY - July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial Board, including our new Co-Editor-in-Chief, Dr. Wafik S. El-Deiry.

Joining Dr. El-Deiry on Oncotarget’s Editorial Board are Dr. Trever Bivona, Dr. Phillip Buckhaults, Dr. Fred Bunz, Dr. Jonathan Chernoff, Dr. Stephen G. Chun, Dr. Nathan Dolloff, Dr. Peiwen Fei, Dr. Justin D. Lathia, Dr. Bora Lim, Dr. Jia
... continue reading >>

Improved Efficacy of Pembrolizumab When Combined With sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC



2024-07-22

“Future development for sEphB4-HSA in HNSCC is likely to focus on patients with HPV-negative disease where there is greatest need to improve on the outcomes with pembrolizumab monotherapy.”

 

 

BUFFALO, NY- July 22, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 10, 2024, entitled, “Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.”

 

Patients with relapsed or metastatic head... continue reading >>

DDX41’s Unique Contribution to Myeloid Leukemogenesis



2024-07-19

“[...] myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms.”

 

 

BUFFALO, NY- July 19, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, “DDX41 and its unique contribution to myeloid leukemogenesis.”

 

In this new editorial, researcher Hirotaka Matsui, from the National Cancer Center Hospital in Tokyo, Japan, and Kumamoto University, discusses... continue reading >>

Using Early On-treatment ctDNA Measurements as Response Assessment in Metastatic Castration Resistant Prostate Cancer



2024-07-17

“[...] results of Tolmeijer et al. show the promise of on-treatment ctDNA detection as early read out for treatment response to potentially help guide treatment management of patients with mCRPC.”

 

 

BUFFALO, NY- July 17, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, “Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer.”

 

In this new editorial, researchers S.H.... continue reading >>

HER2-low and HER2-zero in Breast Cancer



2024-07-16

“[...] we found an independent positive prognostic effect of HER2-low compared to HER2-zero in early breast cancer.”

 

 

BUFFALO, NY- July 16, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity.”

 

In this new editorial, researchers Marcus Schmidt, Hans-Anton Lehr, and Katrin Almstedt from the University Medical Center of Johannes Gutenberg University discuss HER2 in... continue reading >>

Comparison of FDG-PET/CT and CT for Treatment Evaluation of Patients With Unresectable Malignant Pleural Mesothelioma



2024-07-15

“FDG-PET is generally considered as a useful metabolic evaluation tool, while it is also thought to have an emerging role for assessment of systemic therapy response.”

 

 

BUFFALO, NY- July 15, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.”

 

Mali... continue reading >>

Targeting ABC Transporters in PDAC



2024-07-10

“[...] it is crucial for the future application of ABC transporter inhibitors [...] to develop a stratification protocol [...] to identify those PDAC patients who are most likely to benefit from chemosensitization induced by these inhibitors.”

 

 

BUFFALO, NY- July 10, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Targeting ABC transporters in PDAC – past, present, or future?

 

In this new editorial, Cecilia Bergonzini, Elisa Giovannetti and ... continue reading >>

Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers



2024-07-08

“In this study, we investigated the therapeutic effects and the underlying mechanisms of TAS-102 in combination with regorafenib against gastrointestinal cancers.”

 

 

BUFFALO, NY- July 8, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, “Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status... continue reading >>

Editorial: Genomics Has More to Reveal



2024-07-02

“If there was any doubt, this discovery demonstrates that genomics, extensively deployed over the past two decades, still has much to reveal to us.”


 

BUFFALO, NY- July 2, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Genomics has more to reveal.”

 

In this new editorial, researchers Laurène Fenwarth and Nicolas Duployez from the University of Lille and CHU Lille discuss molecular and cytogenetic analyses that are now used to identify... continue reading >>

Starving Cancer Cells Enhances DNA Damage and Immunotherapy Response



2024-06-26

“Depleting amino acid[s] likely expose[s] the Achilles heel of the cancer and exacerbate[s] DNA repair-targeted and immune-based therapy response.”


 

BUFFALO, NY- June 26, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Starving cancer cells to enhance DNA damage and immunotherapy response.”

 

Prostate cancer (PCa) poses significant challenges in treatment, particularly when it progresses to a metastatic, castrate-resistant state.... continue reading >>

Gold Nanostars for Precision Laser Interstitial Thermal Therapy



2024-06-24

“Gold nanostars amplify brain-tumor selective laser interstitial thermal therapy.”


 

BUFFALO, NY- June 24, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 14, 2024, entitled, “Leveraging gold nanostars for precision laser interstitial thermal therapy.”

 

In this new editorial, researchers Aden P. Haskell-Mendoza, Ethan S. Srinivasan, Tuan Vo-Dinh and Peter E. Fecci from Duke University discuss laser interstitial thermal therapy (LITT). Over the past decade, LITT has ... continue reading >>

Assessment of CEA, CA-125, and CA19-9 as Adjuncts in Non-small Cell Lung Cancer Management



2024-06-19

“[...] these inexpensive, widely available tests with rapid turnaround times and relatively short half-lives (CEA, CA-125, and CA19-9) are perfectly situated to serve as adjunctive clinical tools in the management of NSCLC.”


 

BUFFALO, NY- June 19, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 13, 2024, entitled, “Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management.”

 

Conventional tumor markers may serve... continue reading >>

Research Perspective: When Does a Melanoma Metastasize? Implications for Management



2024-06-18

“[...] immunotherapy is more likely to be effective at eliminating metastatic disease if the tumor burden is low, making it more logical to treat patients with high-risk melanomas at the earliest possible time [...]”


 

BUFFALO, NY- June 18, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 13, 2024, entitled, “When does a melanoma metastasize? Implications for management.”

 

In this new perspective, researchers John F. Thompson and Gabrielle J. Williams from The... continue reading >>

Oncotarget Sponsors 2024 Ride for Roswell



2024-06-11

Impact Journals (Oncotarget's publisher) is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell.

 

 

BUFFALO, NY- June 11, 2024 – The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 28 years to celebrate cancer survivors, pay tribute to... continue reading >>

Synergistic Cytotoxicity of HDAC and PARP Inhibitors and Decitabine in Pancreatic Cancer Cells: Implications for Novel Therapy



2024-06-05

“The results provide novel preclinical data that demonstrate synergism between HDACi- and PARPi-mediated inhibition of DNA repair and decitabine in pancreatic cancer [...]”


 

BUFFALO, NY- June 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 3, 2024, entitled, “Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.”

 

Histone deacetylase inhibitors (HDACi)... continue reading >>

BTK Inhibitor-related Cardiotoxicity: The Quest for Predictive Biomarkers and Improved Risk Stratification



2024-06-04

“[...] due to the general lack of robust predictive biomarkers, a standardized risk stratification tool is not utilized in clinical practice – a prime area for research.”


 

BUFFALO, NY- June 4, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 3, 2024, entitled, “Bruton’s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.”

 

In this new perspective, researchers Jai N. Patel, Jai Singh, and... continue reading >>

Silibinin: An Old and New Molecule in Cancer Therapies



2024-05-28

“This consideration could be the starting point to study whether Silibinin could contrast tumor progression, aging and inflammaging through molecular and cellular mechanisms [...].”

 

 

BUFFALO, NY- May 28, 2024 – A new review paper was published in Oncotarget's Volume 15 on May 23, 2024, entitled, “The importance of integrated therapies on cancer: Silibinin, an old and new molecule.”

 

In this new review, researchers Elisa Roca, Giuseppe Colloca, Fiorella Lombardo, Andrea Bellieni, Alessandra ... continue reading >>

GZ17-6.02 Kills Uveal Melanoma Cells



2024-05-22

“The present studies demonstrated that GZ17-6.02 interacted with irreversible inhibitors of the EGF receptor and HER2 to kill uveal melanoma cells.”

 

BUFFALO, NY- May 22, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 17, 2024, entitled, “GZ17-6.02 kills PDX isolates of uveal melanoma.”

 

In this new study, researchers Laurence Booth, Jane L. Roberts, Ivan Spasojevic, Kaitlyn C. Baker, Andrew Poklepovic, Cameron West, John M. Kirkwood, and Paul Dent from Virginia... continue reading >>

Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167 via EMT and Antiviral Immune Response



2024-05-20

“[...] we have characterized a pair of compounds that impact multiple processes that are relevant to cancer cell proliferation but also, and possibly more importantly, to metastasis [...].”

 

 

BUFFALO, NY- May 20, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 16, 2024, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.”

 

The... continue reading >>

Expression of Cyclin D1 in Penile Cancer



2024-05-15

“Brazil holds the global record for penile cancer incidence.”

 

 

BUFFALO, NY- May 15, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 14, 2024, entitled, “Cyclin D1 expression in penile cancer.”

 

In this new study, researchers Wesliany Everton Duarte, Jaqueline Diniz Pinho, Syomara Pereira da Costa Melo, Denner Rodrigo Diniz Duarte, Juliana Martins da Guia Ribeiro do Carmo, André Salim Khayat, José Ribamar Rodrigues Calixto, Marcos Adriano Garcia Campos, Rita da Graç... continue reading >>

Oncotarget at SSP 46th Annual Meeting



2024-05-13

Oncotarget is proud to participate at the Society for Scholarly Publishing (SSP) 46th Annual Meeting, which convenes May 29–31, 2024, in Boston, Massachusetts.


BUFFALO, NY- May 13, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences, with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals.

Impact Journals is proud to participate as an exhibitor at the Society for Scholarly Publishing (SSP)... continue reading >>

Deep Learning-based Whole-body Prostate-specific Membrane Antigen PET/CT Attenuation Correction



2024-05-08

“We have developed a Pix-2-Pix GAN model to perform attenuation correction on whole-body PSMA [prostate-specific membrane antigen] PET images with 18F-DCFPyL.”

 

 

BUFFALO, NY- May 8, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 7, 2024, entitled, “Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN.”

 

The sequential PET/CT studies oncology patients can undergo during their treatment follow-up course is limited by radiation... continue reading >>

Transfected SARS-CoV-2 Spike DNA Suppresses Cancer Cell Response to Chemotherapy



2024-05-06

“Our findings have implications for the natural history of prolonged or repeated SARS-CoV-2 infection as well as design of anti-COVID-19 vaccines that are administered repeatedly as booster shots.”

 

 

BUFFALO, NY- May 6, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 3, 2024, entitled, “Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer... continue reading >>

Oncotarget Sponsors 19th International p53 Workshop in Italy



2024-04-29

Oncotarget is a contributing sponsor at the 19th International p53 Workshop in Trieste, Italy, on May 13–16, 2024.

 

 

BUFFALO, NY- April 29, 2024 – Oncotarget is a contributing sponsor at the 19th International p53 Workshop, organized by the International Center for Genetic Engineering and Biotechnology (ICGEB), which takes place from May 13–16, 2024, in Trieste, Italy.

 

“Groundbreaking research and cutting-edge advancements in the field of the most studied human gene and most frequently... continue reading >>

Novel Therapeutic Bispecific Antibodies for B-cell Lymphoma



2024-04-16

“Our results indicate that IgM-dependent bispecific antibodies are potent therapeutic agents for B-cell malignancies.”


 

BUFFALO, NY- April 16, 2024 – A new research paper was published in Oncotarget's Volume 15 on April 12, 2024, entitled, “Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface.”

 

The B-cell receptor regulates B-cell proliferation and apoptosis. Aberrations in BCR signaling are associated with the development and... continue reading >>

Exploring the Role of MIA-602 in Overcoming Doxorubicin-resistance in Acute Myeloid Leukemia



2024-04-10

“Our results reveal that MIA-602 may be a useful treatment for Doxorubicin-resistant AML [...]”


 

BUFFALO, NY- April 10, 2024 – A new research paper was published in Oncotarget's Volume 15 on April 8, 2024, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.”

 

Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include... continue reading >>

Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer



2024-03-27

“[...] this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]”


 

BUFFALO, NY- March 27, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 19, 2024, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.”

 

In this new study, researchers Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong... continue reading >>

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells



2024-03-25

“[...] the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.”


 

BUFFALO, NY- March 25, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.”

 

ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML... continue reading >>

Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal®



2024-03-20

“These results suggest strong potential for clinical use of the assay in ctDNA monitoring of solid tumor cancers.”


 

BUFFALO, NY- March 20, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, “Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.”

 

In this new study, researchers Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C.P. Navarro, Rachel Marty Pyke, Manqing Hong, Qi Zhang,... continue reading >>

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny



2024-03-19

“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.”


 

BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center in Oncotarget's Volume 15 on March 15, 2024, entitled, “From osimertinib to preemptive combinations.”

 

“Here, I suggest that while first-line osimertinib extends median progression-free survival (PFS) in EGFR-mutant lung cancer compared to... continue reading >>

A New Antibody Capture Method Reveals G-quadruplex Landscape and its Regulation



2024-03-18

“[...] we present an improved method for G4 landscape determination and by applying it we show that sequence property-specific constraints of the nuclear environment mitigate G4 formation.”

 

 

BUFFALO, NY- March 18, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 14, 2024, entitled, “G-quadruplex landscape and its regulation revealed by a new antibody capture method.”

 

In this new study, researchers Subhamoy Datta, Manthan Patel, Chakkarai Sathyaseelan, Chandrama ... continue reading >>

Oncotarget at AACR Annual Meeting 2024



2024-03-11

Oncotarget is proud to participate at the American Association for Cancer Research (AACR) Annual Meeting 2024, which convenes April 5-10 in San Diego, California.


BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals

Impact Journals will be participating as an exhibitor at the American Association for Cancer... continue reading >>

GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells



2024-03-06

“We believe that developing GZ17-6.02 as a novel multiple myeloma agent potentially opens up a multitude of novel opportunities to develop therapeutic approaches which will prolong patient survival.”


 

BUFFALO, NY- March 6, 2024 – A new research paper was published in Oncotarget's Volume 15 on March 5, 2024, entitled, “GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.”

 

In this new study, researchers Laurence Booth, Jane L. Roberts, Cameron West, and Paul Dent from ... continue reading >>

Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas



2024-03-04

“[...] these results support the rationale and potential for favorable clinical outcomes of combining SG therapy with platinum-based chemotherapeutics in solid tumors.”


 

BUFFALO, NY- March 4, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.”

 

Sacituzumab govitecan (SG) is an ... continue reading >>

BRCA1 and BRCA2 in a Cohort of Ovarian Cancer Patients From the Salento Peninsula



2024-02-28

“Ovarian cancer (OC) is the third most prevalent type of gynecologic cancer affecting women after cervical and uterine cancer [1]. It is also considered the most fatal of all gynecological cancers [...]”


 

BUFFALO, NY- February 28, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 22, 2024, entitled, “Prevalence and spectrum of germline BRCA1 and BRCA2 in a cohort of ovarian cancer patients from the Salento peninsula (Southern Italy): a matter of preventive health.”... continue reading >>

GZ17-6.02 With Bexarotene Kills Mycosis Fungoides Cells



2024-02-26

“The present studies were performed to extend our knowledge of GZ17-6.02 biology from that known in solid tumor cell types such as prostate cancer cells to liquid tumor cell types, for example, mycosis fungoides.”


 

BUFFALO, NY- February 26, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 8, 2024, entitled, “GZ17-6.02 interacts with bexarotene to kill mycosis fungoides cells.”

 

In this new study, researchers Michael R. Booth, Laurence Booth, Jane L. Roberts,... continue reading >>

Combining Causal and Correlative Approaches to Discover Response Biomarkers to Paclitaxel



2024-02-21

“The discovery of predictive biomarkers to paclitaxel vulnerability [such] as SSR3 [signal sequence receptor 3] promises to significantly impact cancer treatment.”


 

BUFFALO, NY- February 21, 2024 – A new research perspective was published in Oncotarget's Volume 15 on February 8, 2024, entitled, “Combining causal and correlative approaches to discover biomarkers of response to paclitaxel.”

 

As discussed in this new paper, researchers Alberto Moscona-Nissan, Karl J. Habashy, Victor A. Arrieta,... continue reading >>

NTRK Gene Fusion in Papillary Thyroid Cancer: A Clinicogenomic Biobank and Record Linkage Study From Finland



2024-02-19

“Estimates of the frequency of NTRK gene fusion in large cohorts of patients with solid tumors come from a limited number of studies. [...]. We aimed to address this gap by evaluating patients with papillary thyroid cancer (PTC) from Finland [...]”


 

BUFFALO, NY- February 19, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage ... continue reading >>

Genetic and Therapeutic Landscapes in Cohort of Pancreatic Adenocarcinomas Using NGS and Machine Learning



2024-02-14

“Our study was designed to build specific mutational and therapeutic landscapes of pancreatic cancer among the Russian population.”


 

BUFFALO, NY- February 14, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Genetic and therapeutic landscapes in cohort of pancreatic adenocarcinomas: next-generation sequencing and machine learning for full tumor exome analysis.”

 

About 7% of all cancer deaths are caused by pancreatic cancer (PCa). PCa is known ... continue reading >>

Differential Expression of Mad2 Gene in Human Esophageal Cancer



2024-02-12

“[...] people of the northeastern region [of India] consume betel quid, consisting of raw areca nut [...]. People often swallow the entire betel-quid after chewing, which is believed to contribute to the development of oral, esophageal, and gastric cancers.”


 

BUFFALO, NY- February 12, 2024 – A new research paper was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Differential expression of Mad2 gene is consequential to the patterns of histone H3 post-translational... continue reading >>

Evaluation of Ruxolitinib, a Janus Kinase Inhibitor, in Multiple Myeloma



2024-02-07

“[...] the results of the studies presented in this review will hopefully provide the impetus for conducting additional preclinical and clinical studies to evaluate RUX in the setting of MM as well as other types of cancer.”


 

BUFFALO, NY- February 7, 2024 – A new research perspective was published in Oncotarget's Volume 15 on February 5, 2024, entitled, “Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.”

 

In this new paper, researchers Ashley... continue reading >>

Drug Discovery in Academia; Dumping in the Publication Landfill?



2024-02-05

“[...] fruitful efforts to bring more drugs from bench to bedside could only be possible if we do not leave them ‘midway’!”


 

BUFFALO, NY- February 5, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “The fate of drug discovery in academia; dumping in the publication landfill?

 

In this new editorial, researchers Uzma Saqib, Isaac S. Demaree, Alexander G. Obukhov, Mirza S. Baig, Amiram Ariel, and Krishnan Hajela, from Devi Ahilya... continue reading >>

BCAS1 Defines a Heterogeneous Cell Population in Diffuse Glioma Patients



2024-01-31

“[...] this is the first study describing a BCAS1+ cell population in a large cohort of diffuse glioma patients.”


 

BUFFALO, NY- January 31, 2024 – A new research paper was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “BCAS1 defines a heterogeneous cell population in diffuse gliomas.”

 

Oligodendrocyte precursor markers have become of great interest to identify new diagnostic and therapeutic targets for diffuse gliomas, since state-of-the-art studies point towards immature ... continue reading >>

Genetic Alterations in Thyroid Cancer Mediate Resistance to BRAF Inhibition and Anaplastic Transformation



2024-01-29

“An improved understanding of the molecular basis of thyroid cancer has led to the development of new targeted agents.”


 

BUFFALO, NY- January 29, 2024 – A new research perspective was published in Oncotarget's Volume 15 on January 24, 2024, entitled, “Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.”

 

In this new paper, researchers Mark Lee and Luc GT Morris from New York Presbyterian Hospital and Memorial Sloan Kettering Cancer ... continue reading >>

Case Report: Lazarus Effect in a Patient Treated With Osimertinib for NSCLC With Leptomeningeal Disease



2024-01-24

“[...] this case supports a body of literature noting potentially dramatic clinical benefits of administering appropriate oncogene directed targeted therapy [...]”


 

BUFFALO, NY- January 24, 2024 – A new case report was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report.”

 

Osimertinib has been shown to be... continue reading >>

Bone Marrow Adipocytes Provide Early Sign of Progression From MGUS to Multiple Myeloma



2024-01-22

“[...] bone marrow adipocyte density, size, and roundness are significantly different between [MGUS and MM] and could provide early signs for progression [...] to MM.”


 

BUFFALO, NY- January 22, 2024 – A new research perspective was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma.”

 

Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal... continue reading >>

ATR Inhibition Using Gartisertib in Patient-derived Glioblastoma Cell Lines



2024-01-17

“[...] this study identifies gartisertib as a potent ATRi within patient-derived glioblastoma cell lines.”


 

BUFFALO, NY- January 17, 2024 – A new research paper was published in Oncotarget's Volume 15 on January 16, 2024, entitled, “ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.”

 

Glioblastoma cells can restrict the DNA-damaging effects of temozolomide (TMZ) and radiation therapy (RT) using the... continue reading >>

Reductive Carboxylation of Glutamine as a Potential Target in AML



2024-01-16

“Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.”


 

BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 1, 2023, entitled, “Reductive carboxylation of glutamine as a potential target in acute myeloid leukemia.”

 

In this new editorial, researchers Alessia Roma, Lawrence D. Goodridge and Paul A. Spagnuolo from the University of Guelph discuss acute myeloid leukemia (AML) — an aggressive cancer of... continue reading >>

Toward Treating PARP Inhibitor-resistant Ovarian Cancers



2024-01-10

“This initiative is geared towards identifying additional biomarkers that can aid in selecting the most appropriate treatments for ovarian cancer.”


 

BUFFALO, NY- January 10, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 22, 2023, entitled, “One more step toward treatment of PARP inhibitor-resistant ovarian cancers.”

 

Over 80% of ovarian cancer cases experience recurrence, resulting in roughly 12,000 annual deaths in the United States. While targeted... continue reading >>

Transformation-associated Recombination (TAR) Cloning and Its Applications



2024-01-08

“TAR cloning is used to genetically engineer synthetic viruses with novel properties that may be used for the development of new vaccines.”


BUFFALO, NY- January 8, 2024 – A new review paper was published in Oncotarget's Volume 14 on December 22, 2023, entitled, “Transformation-associated recombination (TAR) cloning and its applications for gene function; genome architecture and evolution; biotechnology and biomedicine.”

Transformation-associated recombination (TAR) cloning represents a unique... continue reading >>

Harnessing Cancer Stem Cell-derived Exosomes



2024-01-03

“[...] recent significant advances in understanding [...] CSC-Exos have revealed numerous potential applications for diagnosis and treatment.”


 

BUFFALO, NY- January 3, 2024 – A new editorial paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, “Therapeutically harnessing cancer stem cell-derived exosomes.”

 

In this editorial, researcher Yong Teng from Emory University discusses cancer stem cell-derived exosomes. Cancer stem cells (CSCs), a small population of cancer... continue reading >>



Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC